Kevin K. Roggin to Adenocarcinoma
This is a "connection" page, showing publications Kevin K. Roggin has written about Adenocarcinoma.
Connection Strength
1.221
-
Prospective clinical trial of diagnostic peritoneal lavage to detect positive peritoneal cytology in patients with gastric cancer. J Surg Oncol. 2013 Jun; 107(8):794-8.
Score: 0.268
-
Extended follow-up after extended lymphadenectomy for gastric cancer: was it worth the wait? Lancet Oncol. 2010 May; 11(5):404-5.
Score: 0.219
-
Cytoreductive Surgery for Selected Patients Whose Metastatic Gastric Cancer was Treated with Systemic Chemotherapy. Ann Surg Oncol. 2021 Aug; 28(8):4433-4443.
Score: 0.115
-
Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treatment Strategy for Metastatic Disease. Cancer Discov. 2021 02; 11(2):308-325.
Score: 0.114
-
Human Organoids Share Structural and Genetic Features with Primary Pancreatic Adenocarcinoma Tumors. Mol Cancer Res. 2019 01; 17(1):70-83.
Score: 0.098
-
Laparoscopic pancreaticoduodenectomy for adenocarcinoma provides short-term oncologic outcomes and long-term overall survival rates similar to those for open pancreaticoduodenectomy. Am J Surg. 2017 Mar; 213(3):512-515.
Score: 0.087
-
Neoadjuvant external beam radiation is associated with No benefit in overall survival for early stage pancreatic cancer. Am J Surg. 2017 Mar; 213(3):521-525.
Score: 0.087
-
Perioperative chemotherapy is associated with a survival advantage in early stage adenocarcinoma of the pancreatic head. Surgery. 2016 09; 160(3):714-24.
Score: 0.084
-
Paraduodenal pancreatitis (groove pancreatitis) mimicking pancreatic adenocarcinoma. Clin Gastroenterol Hepatol. 2012 Jan; 10(1):A31-2.
Score: 0.060
-
Limitations of ampullectomy in the treatment of nonfamilial ampullary neoplasms. Ann Surg Oncol. 2005 Dec; 12(12):971-80.
Score: 0.040
-
Evaluation of the Association of Perioperative UGT1A1 Genotype-Dosed gFOLFIRINOX With Margin-Negative Resection Rates and Pathologic Response Grades Among Patients With Locally Advanced Gastroesophageal Adenocarcinoma: A Phase 2 Clinical Trial. JAMA Netw Open. 2020 02 05; 3(2):e1921290.
Score: 0.027
-
Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma. Cancer Discov. 2018 01; 8(1):37-48.
Score: 0.023